Skip to main content

Advertisement

Table 7 Evaluation of differences in prevalence of HPV infected breast cancer patients among different studies

From: Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins

Study Year/Country HPV+ patients HPV+ controls Most prevalent HPV
Current study 2017/Iran 48.6% 16.1% HPV-18 (22.2%)
Islam et al. 2017/India 63.9% 9.5% HPV-16 (69%)
Salman et al. 2017/UK 42% 17% HPV-39 (20%)
Fernandes et al. 2015/ Venezuela 41.6% NA HPV-51 (30.7%)
Herrera-Goepfert et al. 2013/Mexico 40% NA HPV-16 (87.5%)
Sigaroodi et al. 2012/Iran 25.9% 2.4% HPV-16 and 18 (both 25%)
Khan et al. 2008/Japan 21% NA HPV-16 (92%)
Yu et al. 2000/China 43.8% NA HPV-33 (43.8%)